Nieto MA, Huang RY, Jackson RA, Thiery JP. Emt: 2016. Cell. 2016;166:21–45.

Article  CAS  PubMed  Google Scholar 

Micalizzi DS, Farabaugh SM, Ford HL. Epithelial-mesenchymal transition in cancer: parallels between normal development and tumor progression. J Mammary Gland Biol Neoplasia. 2010;15:117–34.

Article  PubMed  PubMed Central  Google Scholar 

Cano A, Perez-Moreno MA, Rodrigo I, Locascio A, Blanco MJ, del Barrio MG, Portillo F, Nieto MA. The transcription factor snail controls epithelial-mesenchymal transitions by repressing E-cadherin expression. Nat Cell Biol. 2000;2:76–83.

Article  CAS  PubMed  Google Scholar 

Batlle E, Sancho E, Franci C, Dominguez D, Monfar M, Baulida J. Garcia De Herreros A: the transcription factor snail is a repressor of E-cadherin gene expression in epithelial tumour cells. Nat Cell Biol. 2000;2:84–9.

Article  CAS  PubMed  Google Scholar 

Celia-Terrassa T, Kang Y. How important is EMT for cancer metastasis? PLoS Biol. 2024;22:e3002487.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Brabletz T. To differentiate or not–routes towards metastasis. Nat Rev Cancer. 2012;12:425–36.

Article  CAS  PubMed  Google Scholar 

De Craene B, Berx G. Regulatory networks defining EMT during cancer initiation and progression. Nat Rev Cancer. 2013;13:97–110.

Article  PubMed  Google Scholar 

Seyfried TN, Huysentruyt LC. On the origin of cancer metastasis. Crit Rev Oncog. 2013;18:43–73.

Article  PubMed  PubMed Central  Google Scholar 

Massague J, Obenauf AC. Metastatic colonization by circulating tumour cells. Nature. 2016;529:298–306.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Welch DR, Hurst DR. Defining the hallmarks of metastasis. Can Res. 2019;79:3011–27.

Article  CAS  Google Scholar 

Schmitt M, Jänicke F, Moniwa N, Chucholowski N, Pache L, Graeff H. Tumor-associated urokinase-type plasminogen activator: biological and clinical significance. Biol Chem Hoppe Seyler. 1992;373:611–22.

Article  CAS  PubMed  Google Scholar 

Jänicke F, Schmitt M, Pache L, Ulm K, Harbeck N, Höfler H, Graeff H. Urokinase (uPA) and its inhibitor PAI-1 are strong and independent prognostic factors in node-negative breast cancer. Breast Cancer Res Treat. 1993;24:195–208.

Article  PubMed  Google Scholar 

Nekarda H, Schlegel P, Schmitt M, Stark M, Mueller JD, Fink U, Siewert JR. Strong prognostic impact of tumor-associated urokinase-type plasminogen activator in completely resected adenocarcinoma of the esophagus. Clin Cancer Res. 1998;4:1755–63.

CAS  PubMed  Google Scholar 

Schmalfeldt B, Kuhn W, Reuning U, Pache L, Dettmar P, Schmitt M, Jänicke F, Höfler H, Graeff H. Primary tumor and metastasis in ovarian cancer differ in their content of urokinase-type plasminogen activator, its receptor, and inhibitors types 1 and 2. Cancer Res. 1995;55:3958–63.

CAS  PubMed  Google Scholar 

Heiss MM, Babic R, Allgayer H, Gruetzner KU, Jauch KW, Loehrs U, Schildberg FW. Tumor-associated proteolysis and prognosis: new functional risk factors in gastric cancer defined by the urokinase-type plasminogen activator system. J Clin Oncol. 1995;13:2084–93.

Article  CAS  PubMed  Google Scholar 

Allgayer H, Heiss MM, Riesenberg R, Grützner KU, Tarabichi A, Babic R, Schildberg FW. Urokinase plasminogen activator receptor (uPA-R): one potential characteristic of metastatic phenotypes in minimal residual tumor disease. Cancer Res. 1997;57:1394–9.

CAS  PubMed  Google Scholar 

Allgayer H, Babic R, Grützner KU, Beyer BC, Tarabichi A, Schildberg FW, Heiss MM. Tumor-associated proteases and inhibitors in gastric cancer: analysis of prognostic impact and individual risk protease patterns. Clin Exp Metastasis. 1998;16:62–73.

Article  CAS  PubMed  Google Scholar 

Allgayer H, Heiss MM, Schildberg FW. Prognostic factors in gastric cancer. Br J Surg. 1997;84:1651–64.

CAS  PubMed  Google Scholar 

Dvorak HF. Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. N Engl J Med. 1986;315:1650–9.

Article  CAS  PubMed  Google Scholar 

Liotta LA. Tumor invasion and metastases–role of the extracellular matrix: rhoads memorial award lecture. Cancer Res. 1986;46:1–7.

CAS  PubMed  Google Scholar 

McIntyre JO, Matrisian LM. Molecular imaging of proteolytic activity in cancer. J Cell Biochem. 2003;90:1087–97.

Article  CAS  PubMed  Google Scholar 

Stetler-Stevenson WG, Krutzsch HC, Wacher MP, Margulies IM, Liotta LA. The activation of human type IV collagenase proenzyme. Sequence identification of the major conversion product following organomercurial activation. J Biol Chem. 1989;264:1353–6.

Article  CAS  PubMed  Google Scholar 

Stetler-Stevenson WG, Hewitt R, Corcoran M. Matrix metalloproteinases and tumor invasion: from correlation and causality to the clinic. Semin Cancer Biol. 1996;7:147–54.

Article  CAS  PubMed  Google Scholar 

Liotta LA, Stetler-Stevenson WG. Metalloproteinases and cancer invasion. Semin Cancer Biol. 1990;1:99–106.

CAS  PubMed  Google Scholar 

Maurer GD, Leupold JH, Schewe DM, Biller T, Kates RE, Hornung HM, Lau-Werner U, Post S, Allgayer H. Analysis of specific transcriptional regulators as early predictors of independent prognostic relevance in resected colorectal cancer. Clin Cancer Res. 2007;13:1123–32.

Article  CAS  PubMed  Google Scholar 

Harbeck N, Schmitt M, Paepke S, Allgayer H, Kates RE. Tumor-associated proteolytic factors uPA and PAI-1: critical appraisal of their clinical relevance in breast cancer and their integration into decision-support algorithms. Crit Rev Clin Lab Sci. 2007;44:179–201.

Article  CAS  PubMed  Google Scholar 

Schmitt M, Harbeck N, Thomssen C, Wilhelm O, Magdolen V, Reuning U, Ulm K, Höfler H, Jänicke F, Graeff H. Clinical impact of the plasminogen activation system in tumor invasion and metastasis: prognostic relevance and target for therapy. Thromb Haemost. 1997;78:285–96.

Article  CAS  PubMed  Google Scholar 

Schewe DM, Leupold JH, Boyd DD, Lengyel ER, Wang H, Gruetzner KU, Schildberg FW, Jauch KW, Allgayer H. Tumor-specific transcription factor binding to an activator protein-2/Sp1 element of the urokinase-type plasminogen activator receptor promoter in a first large series of resected gastrointestinal cancers. Clin Cancer Res. 2003;9:2267–76.

CAS  PubMed  Google Scholar 

Schewe DM, Biller T, Maurer G, Asangani IA, Leupold JH, Lengyel ER, Post S, Allgayer H. Combination analysis of activator protein-1 family members, Sp1 and an activator protein-2alpha-related factor binding to different regions of the urokinase receptor gene in resected colorectal cancers. Clin Cancer Res. 2005;11:8538–48.

Article  CAS  PubMed  Google Scholar 

Beyer BC, Heiss MM, Simon EH, Gruetzner KU, Babic R, Jauch KW, Schildberg FW, Allgayer H. Urokinase system expression in gastric carcinoma: prognostic impact in an independent patient series and first evidence of predictive value in preoperative biopsy and intestinal metaplasia specimens. Cancer. 2006;106:1026–35.

Article  CAS  PubMed  Google Scholar 

Heiss MM, Allgayer H, Gruetzner KU, Funke I, Babic R, Jauch KW, Schildberg FW. Individual development and uPA-receptor expression of disseminated tumour cells in bone marrow: a reference to early systemic disease in solid cancer. Nat Med. 1995;1:1035–9.

Article  CAS  PubMed  Google Scholar 

Allgayer H, Heiss MM, Riesenberg R, Babic R, Jauch KW, Schildberg FW. Immunocytochemical phenotyping of disseminated tumor cells in bone marrow by uPA receptor and CK18: investigation of sensitivity and specificity of an immunogold/alkaline phosphatase double staining protocol. J Histochem Cytochem. 1997;45:203–12.